Ligand Pharmaceuticals Incorporated (LGND): Price and Financial Metrics

Ligand Pharmaceuticals Incorporated (LGND): $79.81

0.73 (-0.91%)

POWR Rating

Component Grades








Add LGND to Watchlist
Sign Up

Industry: Biotech




#35 of 348

in industry

LGND Price/Volume Stats

Current price $79.81 52-week high $94.57
Prev. close $80.54 52-week low $49.24
Day low $79.33 Volume 69,600
Day high $81.01 Avg. volume 151,766
50-day MA $79.84 Dividend yield N/A
200-day MA $69.60 Market Cap 1.44B

LGND Stock Price Chart Interactive Chart >

Ligand Pharmaceuticals Incorporated (LGND) Company Bio

Ligand Pharmaceuticals develops therapies that address the unmet medical needs of patients for a range of diseases, including hepatitis, multiple myeloma, muscle wasting, Alzheimer’s disease, dyslipidemia, diabetes, anemia, epilepsy, focal segmental glomerulosclerosis, and osteoporosis. The company was founded in 1987 and is based in La Jolla, California.

LGND Latest News Stream

Event/Time News Detail
Loading, please wait...

LGND Latest Social Stream

Loading social stream, please wait...

View Full LGND Social Stream

Latest LGND News From Around the Web

Below are the latest news stories about LIGAND PHARMACEUTICALS INC that investors may wish to consider to help them evaluate LGND as an investment opportunity.

13 Most Promising Small-Cap Stocks According to Analysts

In this piece, we will take a look at the 13 most promising small-cap stocks according to analysts. If you want to skip our overview of small cap investing and the latest stock market news, then you can take a look at the 5 Most Promising Small-Cap Stocks To Buy. Within the broader world of […]

Yahoo | December 27, 2023

Ligand Pharmaceuticals (LGND) Just Overtook the 200-Day Moving Average

Good things could be on the horizon when a stock surpasses the 200-day simple moving average. How should investors react?

Yahoo | December 14, 2023

Ligand (LGND) Posts Long-Term Outlook, Updates Portfolio Progress

Ligand (LGND) aims to generate annual core sales of around $290 million by 2028. It expects revenues from royalties to witness a CAGR of 16% over the next five years.

Yahoo | December 13, 2023

Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance

SAN DIEGO, December 12, 2023--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) hosted an Investor and Analyst Day in New York City earlier today. CEO Todd Davis and other members of Ligand’s senior management team provided an overview of the company’s business model and investment selection process, reviewed the progress of the portfolio including near-term partner milestones, and introduced 2024 guidance. A copy of the presentation and a replay of the webcast are available at investor.ligand.

Yahoo | December 12, 2023

Sermonix Pharmaceuticals Shares Pharmacokinetic and Baseline Genomic Clinical Data Tied to ELAINE Lasofoxifene Trials of Patients With ESR1 Mutations

Three posters examining ELAINE clinical trials were presented last week at SABCSCOLUMBUS, Ohio, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC) harboring ESR1 mutations, today broadly shared the three poster presentations examining clinical data tied to Sermonix’s Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE) studies. The presentations were

Yahoo | December 12, 2023

Read More 'LGND' Stories Here

LGND Price Returns

1-mo -8.56%
3-mo 12.41%
6-mo 11.61%
1-year 5.47%
3-year -38.42%
5-year -28.67%
YTD 11.75%
2023 6.92%
2022 -56.75%
2021 55.31%
2020 -4.64%
2019 -23.15%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!